Tandem Diabetes Q4 Sales Rise 15% to $290.4M Drives 30% Stock Rally
Tandem Diabetes reported Q4 sales of $290.4 million, a 15% year-on-year increase, and a loss of $0.01 per share, beating revenue and earnings estimates. Shares surged 30.2% despite issuing a 2026 sales forecast slightly below market expectations, highlighting investor focus on margin expansion and quarterly performance.
1. Q4 Financial Results Beat Estimates
In the fourth quarter, Tandem Diabetes recorded sales of $290.4 million, a 15% increase year-over-year, and reported a loss of $0.01 per share, outperforming analyst revenue and earnings forecasts. The company also achieved improved operating margins, narrowing losses compared to prior periods.
2. Stock Surge and Guidance Impact
Following the earnings beat, shares jumped 30.2% in the afternoon session as investors prioritized strong quarterly performance and margin expansion. The company’s 2026 sales forecast modestly trailed market expectations, and the stock remains approximately 27.7% below its 52-week high of $33.59.